Add office photos
Employer?
Claim Account for FREE
Lupin
4.2
based on 6k Reviews
Video summary
Company Overview
Associated Companies
Company Locations
Working at Lupin
Company Summary
A leading global pharmaceutical company in India
Overall Rating
4.2/5
based on 6k reviews
8% above
industry average
Highly rated for
Skill development, Company culture, Work-life balance
Work Policy
Work from office
85% employees reported
Monday to Saturday
59% employees reported
Flexible timing
53% employees reported
No travel
47% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
532 employees reported
Health insurance
476 employees reported
Office cab/shuttle
327 employees reported
Cafeteria
211 employees reported
View all benefits
About Lupin
Founded in1968 (57 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersMumbai, Maharashtra, India
Office Locations
Websitelupin.com
Primary Industry
Other Industries
Are you managing Lupin's employer brand? To edit company information,
claim this page for free
View in video summary
Lupin is a global pharmaceutical company offering a wide range of products such as Branded & Generic Formulations, Biotechnology Products, Active Pharmaceutical Ingredients (APIs) and Specialty. Lupin is a significant player in the therapy areas of Gynaecology, Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Lupin also holds a global leadership position in the Anti-TB and Cephalosporins segments. With a presence in over 100 countries, Lupin offers high-quality yet affordable medicines for some of the most chronic diseases addressing unmet needs in many parts of the world.
Managing your company's employer brand?
Claim this Company Page for FREE
Lupin Ratings
based on 6k reviews
Overall Rating
4.2/5
How AmbitionBox ratings work?
5
3.1k
4
1.7k
3
654
2
216
1
355
Category Ratings
4.1
Skill development
4.0
Company culture
3.9
Work-life balance
3.8
Salary
3.8
Work satisfaction
3.7
Job security
3.5
Promotions
Lupin is rated 4.2 out of 5 stars on AmbitionBox, based on 6k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Lupin
based on 5.7k reviews
4.0
Rated by 360 Women
Rated 3.9 for Company culture and 3.8 for Work-life balance
4.2
Rated by 5.4k Men
Rated 4.1 for Skill development and 4.0 for Company culture
Work Policy at Lupin
based on 602 reviews in last 6 months
Work from office
85%
Hybrid
10%
Permanent work from home
5%
Lupin Reviews
Top mentions in Lupin Reviews
+ 5 more
Compare Lupin with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 4.2/5 based on 6k reviews | 4.0/5 based on 5.8k reviews | 4.1/5 based on 6.9k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Skill development Company culture Work-life balance | Salary Skill development Job security | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | No critically rated category | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 85% employees reported | Work from office 82% employees reported | Work from office 72% employees reported | - |
Rating by Women Employees | 4.0 Good rated by 360 women | 4.0 Good rated by 441 women | 4.1 Good rated by 680 women | - no rating available |
Rating by Men Employees | 4.2 Good rated by 5.4k men | 4.0 Good rated by 5k men | 4.1 Good rated by 5.8k men | - no rating available |
Job security | 3.7 Good | 3.8 Good | 3.7 Good | 4.0 Good |
View more
Lupin Salaries
Lupin salaries have received with an average score of 3.8 out of 5 by 6k employees.
Officer
(1.8k salaries)
Unlock
₹1.9 L/yr - ₹8.6 L/yr
Research Associate
(863 salaries)
Unlock
₹2 L/yr - ₹8 L/yr
Production Officer
(657 salaries)
Unlock
₹2.1 L/yr - ₹7 L/yr
Marketing Executive
(622 salaries)
Unlock
₹2.2 L/yr - ₹7.2 L/yr
Senior Officer
(444 salaries)
Unlock
₹2.8 L/yr - ₹7.3 L/yr
Junior Officer
(379 salaries)
Unlock
₹2.5 L/yr - ₹7.9 L/yr
Medical Representative
(370 salaries)
Unlock
₹2 L/yr - ₹6.5 L/yr
Executive Production
(290 salaries)
Unlock
₹3.6 L/yr - ₹12 L/yr
QC Officer
(264 salaries)
Unlock
₹2.6 L/yr - ₹7.3 L/yr
Associate Scientist
(262 salaries)
Unlock
₹5.5 L/yr - ₹18 L/yr
Lupin Interview Questions
Interview questions by designation
Top Lupin interview questions and answers
Get interview-ready with top interview questions
Lupin Jobs
Popular Skills Lupin Hires for
Current Openings
Lupin News
View all
Lupin Shares Rise Post Citi's Double Upgrade, Target Price Hike
- Lupin shares rose after Citi's double upgrade to 'buy' rating and target price hike.
- Citi expects sustained margin strength fueled by good momentum from US launch and positive traction in non-US markets.
- Lupin's base business margin expansion is driven by loss reduction in adjacencies and complex generic launches.
- Despite risks, Citi sees an attractive entry point with positive outlook for Lupin's growth trajectory.
Bloomberg Quint | 5 Mar, 2025
.png?rect=0%2C18%2C483%2C254&w=1200&auto=format%2Ccompress&ogImage=true)
Nalco To Lupin: Stocks That De-Rated Despite Earnings Revision
- Indian markets have witnessed a sharp correction over the last five months due to multiple macro reasons and a cut in overall earnings expectations.
- Out of the 5,684 stocks listed on the BSE, 3,446 stocks have declined in the last five months, while from the NSE Nifty 500, 458 stocks have declined in the same period.
- Certain stocks have been weighed down much more due to macro reasons.
- The article mentions Nalco and Lupin as examples of stocks that have de-rated despite earnings revision.
Bloomberg Quint | 20 Feb, 2025
Q3 Results Highlights: Bharat Forge, Natco Pharma report Q3 profits; Ashok Leyland posts 34.63% rise
- Ashok Leyland reported a net profit of Rs 18.48 crore in the October-December period a year ago, with total income falling to Rs 179.87 crore in Q3 this fiscal, compared to Rs 240.57 crore year-on-year.
- Bharat Forge also posted a profit of Rs 608.85 crore in the third quarter last fiscal.
- Natco Pharma recorded a net profit of Rs 70.24 crore in the same period a year ago.
- Patel Engineering reported a consolidated net profit of ₹1391.5 crore in Q3 FY25 as against ₹1145.3 crore in the previous year's quarter.
- Steel Authority of India Ltd (SAIL) saw a 66.5% decline in net profit to ₹141.9 crore in the Q3 of December 2024, despite a 4.9% rise in revenue from operations.
- Lupin Limited's shares were trading at ₹2,062.15, down by ₹5.45 or 0.26% on the NSE.
- Alpex Solar, Knowledge Marine, Indo Tech Transformers, Khazanchi Jewellers, Ceinsys Tech, and One Point One all reported good to excellent results for Q3, with varying growth rates in sales and profits.
- Gensol, however, reported weak results for the quarter ending December 2024, with a decrease in net profit on a QoQ basis.
- The Navratna PSU's consolidated net profit fell 64.8% to ₹86.1 crore in Q3FY25 from ₹244.7 crore in the same period last year.
- Company's standalone net profit varied across different organizations, with some reporting profits and others losses in the quarter ended December 2024.
- Overall, the performance of various companies varied in Q3, with some showing growth and others facing challenges.
HinduBusinessLine | 12 Feb, 2025
Lupin posts 39% profit jump on strong US sales growth
- Lupin Limited posts a 39% profit jump on strong US sales growth.
- North American sales, accounting for 38% of global revenue, grew by 12.3% to ₹2,121.3 crore.
- The EBITDA margin improved to 25.1% from 21% in the corresponding quarter.
- Lupin received six ANDA approvals from the US FDA and launched two products in the US market.
HinduBusinessLine | 12 Feb, 2025
Lupin Shares Fall Despite 40% Jump In Q3 Profit
- Lupin shares fell as much as 3.30% despite a 40% jump in Q3 profit.
- The share price decline comes as Nifty fell below 23,000 support level and the stock was trading at a high volume.
- Lupin recorded a consolidated net profit of Rs 855 crore for the quarter ended December, exceeding Bloomberg's estimates.
- Revenue increased by 11% YoY for the three months ended December, and India sales grew by 11.9% YoY, accounting for 34% of global sales.
Bloomberg Quint | 12 Feb, 2025
Q3 Results Live: Vodafone Idea, IRCTC, Berger Paints, SAIL, NBCC, Lupin Shares Fall Ahead Of Earnings
- Vodafone Idea, IRCTC, Berger Paints, SAIL, NBCC, Lupin shares fall ahead of Q3 results.
- Vodafone Idea is expected to post a loss of Rs 6,890.3 crore for Q3.
- Vodafone Idea's revenue estimate for Q3 is Rs 11,363.3 crore.
- Other companies announcing Q3 results today include Bayer Cropscience, Birlasoft, Campus Activewear, Cello World, Cera Sanitaryware, Dalmia Bharat Sugar and Industries.
Bloomberg Quint | 11 Feb, 2025
Q3 Results Today: Vodafone Idea, IRCTC, NBCC, Ircon, SAIL Among 330+ Companies To Announce Earnings On Feb. 11
- As many as 334 companies to announce their financial statements for Q3 on Feb. 11.
- Key companies like Vodafone Idea, IRCTC, NBCC, Berger Paints will declare their financial results on this day.
- Other notable companies sharing results include Lupin, Zee Media and Devyani International.
- SAIL declared its Q3 earnings today. Its revenue fell by 17% YoY to Rs. 24,675 crore, while the net profit declined by 31% YoY to Rs. 897 crore.
- IRCTC announced an 8.1% increase in total income to Rs. 1,123 crore and net profit grew 4.5% to Rs. 307.9 crore.
- Berger Paints reported nearly flat revenue of Rs. 2,774 crore, with a YoY decline of 7.6% in its consolidated net profit to Rs. 270 crore.
- This comes as the busiest day of the ongoing Q3 earnings season, with the biggest companies from key performing sectors of the Indian economy sharing their financial reports.
- Other notable companies sharing their reports today include Bajaj Healthcare Ltd., Tata Investment Corporation, Lupin, ZEE Media and Devyani International.
- The earnings season has begun to gain steam in India, with many companies expected to post significant gains thanks to the economic recovery.
- Investors are looking forward to a strong earnings season, which is expected to support the market's recent rally.
Bloomberg Quint | 11 Feb, 2025
Stock Market Live: Gifty Nifty Trades Below 23,500; Fresh US Tariffs On Metals Spark Worries
- The Gifty Nifty was up 0.06% or 9 points to 23,477.50 as of 7:30 a.m.
- Swiggy Ltd., FSN E-Commerce Vantures Ltd. and Eicher Motors Ltd. were among the top companies on brokerages' radar.
- The rupee may trade around 87.40-87.65 range with sideways price action today.
- The Nifty is weak and struggling to maintain higher levels and forming a bearish candle for the past four days.
- Sona BLW Precision Forgings is to purchase a land in Haryana from Escorts Kubota for Rs 110 crore.
- Donald Trump sets 25% tariffs on steel, aluminum.
- Gifty Nifty traded below 23,500 ahead of the stock market opening.
- BP will provide technical services for Mumbai High, India's largest offshore oil field.
- Lupin has obtained approval from the USFDA for its Abbreviated New Drug Application for Ipratropium Bromide Nasal Solution.
- SBFC Finance has received Rs. 400 crore to support low-income and women entrepreneurs in India.
Bloomberg Quint | 11 Feb, 2025
Vodafone Idea, Berger Paints, Lupin, SAIL, MOIL, Procter & Gamble Q3 Results Today — Earnings Estimates
- Vodafone Idea, Berger Paints, Lupin, SAIL, MOIL, and Procter & Gamble are scheduled to announce their Q3 earnings today.
- Vodafone Idea is expected to post a loss of Rs 6,890.3 crore with revenue of Rs 11,363.3 crore.
- Lupin is estimated to report a net profit of Rs 792.6 crore with revenue of Rs 5,686 crore.
- SAIL is projected to report a net loss worth Rs 231.8 crore with revenue of Rs 23,417.1 crore.
Bloomberg Quint | 11 Feb, 2025
Stocks To Watch: Tata Power, Lupin, RVNL, NLC, ICICI Prudential, Alkem Labs
- Tata Power Co.'s consolidated net profit climbed 8% in the third quarter
- Lupin clarified reports about receiving the US FDA approval for a generic HIV drug, saying they have received tentative approval for their Abbreviated New Drug Application
- ICICI Prudential Life Insurance Co received a show-cause notice demanding Rs 492.06 crore
- Rail Vikas Nigam secured a Rs 404.4-crore contract from East Coast Railway for a road doubling project
Bloomberg Quint | 5 Feb, 2025
Powered by
Lupin Subsidiaries
Rubamin
4.1
• 150 reviews
Lupin Digital Health
3.5
• 28 reviews
Polynova Industries
4.2
• 8 reviews
Novel Laboratories Inc
2.0
• 1 review
Report error
Compare Lupin with
Biocon Limited
3.9
Zydus Lifesciences
4.1
Glenmark Pharmaceuticals
3.9
Torrent Pharmaceuticals
3.9
Aurobindo Pharma
4.0
DIVI'S Laboratories
3.7
Alkem Laboratories
3.9
Dr. Reddy's
4.0
Intas Pharmaceuticals
4.1
Hetero
3.9
Viatris
4.2
Alembic Pharmaceuticals
4.0
Abbott
4.1
Ipca Laboratories
3.9
Mankind Pharma
3.9
MSN Laboratories
3.7
Ajanta Pharma
4.1
Akums Drugs & Pharmaceuticals Limited
4.4
GlaxoSmithKline Pharmaceuticals
4.1
Pfizer
4.0
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Lupin
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 5.8k reviews
DRJ & CO
Architecture & Interior Design
5.0
• 1 reviews
Cipla
Manufacturing, Pharma
4.1
• 6.9k reviews
Biocon Limited
Biotech & Life sciences, Biotechnology
3.9
• 1.9k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.1
• 6k reviews
Glenmark Pharmaceuticals
Pharma
3.9
• 2.9k reviews
Torrent Pharmaceuticals
Pharma
3.9
• 2.5k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.8k reviews
DIVI'S Laboratories
Pharma
3.7
• 1.4k reviews
Alkem Laboratories
Healthcare / Pharma, Biotechnology, Pharma
3.9
• 2.9k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 6.8k reviews
Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.4k reviews
Lupin FAQs
When was Lupin founded?
Lupin was founded in 1968. The company has been operating for 57 years primarily in the Pharma sector.
Where is the Lupin headquarters located?
Lupin is headquartered in Mumbai, Maharashtra and has an office in Mumbai
How many employees does Lupin have in India?
Lupin currently has more than 21,000+ employees in India. Research & Development department appears to have the highest employee count in Lupin based on the number of reviews submitted on AmbitionBox.
Does Lupin have good work-life balance?
Lupin has a Work-Life Balance Rating of 3.9 out of 5 based on 6,000+ employee reviews on AmbitionBox. 80% employees rated Lupin 4 or above, while 20% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Lupin work-life balance reviews for more details
Is Lupin good for career growth?
Career growth at Lupin is rated fairly well, with a promotions and appraisal rating of 3.5. 80% employees rated Lupin 4 or above, while 20% employees rated it 3 or below on promotions/appraisal. Though the sentiment is mixed for career growth, majority employees have rated it positively. We recommend reading Lupin promotions/appraisals reviews for more detailed insights.
What are the pros of working in Lupin?
Working at Lupin offers several advantages that make it an appealing place for employees. The company is highly rated for skill development, company culture and work life balance, based on 6,000+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
